606093-58-7

Basic information

• Product Name: Methyl 4-Amino-3-Fluoro-5-Nitro-2-(Phenylamino)Benzoate
• Synonyms: Methyl 4-Amino-3-Fluoro-5-Nitro-2-(Phenylamino)Benzoate;Methyl 4-amino-2-anilino-3-fluoro-5-nitrobenzoate;Benzoicacid, 4-aMino-3-fluoro-5-nitro-2-(phenylaMino)-, Methyl ester;4-Amino-3-fluoro-5-nitro-2-phenylaminobenzoic acid methyl ester
• CAS NO: 606093-58-7
• Molecular Formula: C₁₄H₁₂FN₃O₄
• Molecular Weight: 305.264
• Mol File: 606093-58-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 475.2°C at 760 mmHg
• Flash Point: 241.2°C
• Appearance: /
• Density: 1.441g/cm³
• Vapor Pressure: 3.39E-09mmHg at 25°C
• Refractive Index: 1.66
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: -4.00±0.25(Predicted)
• CAS DataBase Reference: Methyl 4-Amino-3-Fluoro-5-Nitro-2-(Phenylamino)Benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-Amino-3-Fluoro-5-Nitro-2-(Phenylamino)Benzoate(606093-58-7)
• EPA Substance Registry System: Methyl 4-Amino-3-Fluoro-5-Nitro-2-(Phenylamino)Benzoate(606093-58-7)

Safety Data

• Hazardous Substances Data: 606093-58-7(Hazardous Substances Data)

Usage

General Description

Methyl 4-Amino-3-Fluoro-5-Nitro-2-(Phenylamino)Benzoate is a chemical compound with the molecular formula C16H13N3O5F. It is an organic compound with a yellow crystalline appearance and is commonly used in the pharmaceutical industry. Methyl 4-Amino-3-Fluoro-5-Nitro-2-(Phenylamino)Benzoate has several potential applications, including as an intermediate in the synthesis of various pharmaceutical drugs. Its specific chemical properties make it useful for its role in drug development and research. Additionally, it is important to handle this compound with care, as it may have potential hazards and risks associated with its handling and use.

InChI:InChI=1/C14H12FN3O4/c1-22-14(19)9-7-10(18(20)21)12(16)11(15)13(9)17-8-5-3-2-4-6-8/h2-7,17H,16H2,1H3

Upstream product

• 284030-57-5 4-amino-2,3-difluoro-5-nitro-benzoic acid 
• 197520-71-1 2,3,4-trifluoro-5-nitro-benzoic acid 
• 61079-72-9 2,3,4,-trifluorobenzoic acid 
• 284030-58-6 4-Amino-2,3-difluoro-5-nitro-benzoic acid methyl ester 
• 62-53-3 aniline 

Downstream Products

• 1000340-06-6 methyl 5-[(4-bromophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylate 
• 606144-02-9 methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylate 
• 606144-04-1 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylic acid 
• 606144-05-2 5-[(4-bromo-2-chlorophenyl)amino]-N-[2-(ethenyloxy)ethoxy]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxamide 
• 606143-52-6 selumetinib 
• 606093-59-8 7-Fluoro-6-phenylamino-3H-benzoimidazole-5-carboxylic acid methyl ester 
• 606144-42-7 4,5-diamino-3-fluoro-2-phenylamino-benzoic acid methyl ester 

Relevant articles and documents

Substituted benzimidazole compound and composition with compound

The invention provides a substituted benzimidazole compound and a composition with the compound. The substituted benzimidazole compound is a compound of formula (I) as shown in the specification, or apharmaceutically acceptable salt, prodrug, aquo-complex or solvent compound, polycrystalline type compound, stereisomer or isotope variant of the compound. The compound provided by the invention canbe adopted to treat and/or prevent related diseases caused by MEK (Methyl Ethyl Ketone), such as excessive proliferative diseases, pancreatitis, kidney illness, blastocyte cell transplantation and angiogenesis or angiopoiesis related diseases.

N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS

-

N3 alkylated benzimidazole derivatives as MEK inhibitors

Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.